This study looks at a new treatment for metastatic pancreatic adenocarcinoma, which is an advanced stage of cancer that started in the pancreas. The study involves two drugs: ivaltinostat and capecitabine. Ivaltinostat is given through an IV, while capecitabine is a pill. In the first part of the study, called Phase 1b, researchers will find the best dose of ivaltinostat to use with capecitabine. In the second part, called Phase 2, patients will either get both drugs or just capecitabine. Each treatment cycle lasts 21 days, and the response to treatment will be checked every 6 or 9 weeks. The study will include about 70 people.

• Participation could last for several months with regular clinic visits.
• Participants must have previously received certain cancer treatments.
• The study will monitor safety and effectiveness of the treatment.

If you join, you'll get regular check-ups and tests to see how the treatment is working. Researchers will stop the treatment if the cancer worsens or you have severe side effects. Consider the time commitment and your current health status before participating.